AP2005003234A0 - Lectin compositions and methods for modulating an immune response to an antigen. - Google Patents

Lectin compositions and methods for modulating an immune response to an antigen.

Info

Publication number
AP2005003234A0
AP2005003234A0 AP2005003234A AP2005003234A AP2005003234A0 AP 2005003234 A0 AP2005003234 A0 AP 2005003234A0 AP 2005003234 A AP2005003234 A AP 2005003234A AP 2005003234 A AP2005003234 A AP 2005003234A AP 2005003234 A0 AP2005003234 A0 AP 2005003234A0
Authority
AP
ARIPO
Prior art keywords
antigen
modulating
methods
immune response
lectin compositions
Prior art date
Application number
AP2005003234A
Other languages
English (en)
Inventor
Andrew H Segal
Elihu Young
Original Assignee
Genitrix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/224,661 external-priority patent/US7629440B2/en
Application filed by Genitrix Llc filed Critical Genitrix Llc
Publication of AP2005003234A0 publication Critical patent/AP2005003234A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2005003234A 2002-08-20 2003-08-20 Lectin compositions and methods for modulating an immune response to an antigen. AP2005003234A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40482302P 2002-08-20 2002-08-20
US10/224,661 US7629440B2 (en) 2002-08-20 2002-08-20 Lectin compositions and methods for modulating an immune response to an antigen
US48740703P 2003-07-15 2003-07-15
PCT/US2003/026072 WO2004018698A2 (fr) 2002-08-20 2003-08-20 Compositions de lectine et technique de modulation dune reponse a un antigene

Publications (1)

Publication Number Publication Date
AP2005003234A0 true AP2005003234A0 (en) 2005-03-31

Family

ID=31950503

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003234A AP2005003234A0 (en) 2002-08-20 2003-08-20 Lectin compositions and methods for modulating an immune response to an antigen.

Country Status (10)

Country Link
EP (1) EP1573047B1 (fr)
JP (1) JP4892705B2 (fr)
AP (1) AP2005003234A0 (fr)
AU (1) AU2003265523A1 (fr)
BR (1) BR0313650A (fr)
CA (1) CA2496384C (fr)
ES (1) ES2441724T3 (fr)
IL (1) IL166998A (fr)
MX (1) MXPA05001953A (fr)
WO (1) WO2004018698A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060036080A1 (en) * 2004-07-16 2006-02-16 Bossard Mary J Conjugates of GM-CSF moiety and a polymer
CN1306960C (zh) * 2004-11-29 2007-03-28 中国科学院武汉病毒研究所 预防流感病毒的截短的血凝素疫苗及其制备方法
EP1748050A1 (fr) * 2005-07-28 2007-01-31 Rijksuniversiteit Groningen Activation de galectines par ciblage amélioré
CA2617877A1 (fr) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Proteines chimeriques de recepteur de toxines ameliorees et proteines chimeriques de recepteur de toxines pour le traitement prophylactique et therapeutique de l'anthrax
US9427449B2 (en) * 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
FR2893619A1 (fr) * 2005-11-21 2007-05-25 Chu Nice Proteine chimere lectine-defensine
AU2007332987B2 (en) * 2006-08-14 2013-01-10 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2257301B1 (fr) 2008-03-03 2014-01-22 The University of Miami Immunothérapie à base de cellules cancéreuses allogéniques
JP2012507706A (ja) * 2008-11-05 2012-03-29 富士レビオ株式会社 生物学的材料の生物化学的及び／又は生物力学的変化の検知方法及び生物学的材料の分析方法
ES2678143T3 (es) * 2010-01-19 2018-08-09 President And Fellows Of Harvard College Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos
EP2734843A2 (fr) * 2011-07-18 2014-05-28 President and Fellows of Harvard College Molécules manipulées ciblant un microbe et leurs utilisations
HK1200102A1 (en) * 2011-09-20 2015-07-31 西奈山医学院 Influenza virus vaccines and uses thereof
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
AU2013243971B2 (en) * 2012-04-04 2017-01-05 Vaxform Llc Improved adjuvant system for oral vaccine adminstration
CA2871160C (fr) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents convenant a la neutralisation de la grippe
EP2976642A4 (fr) 2013-03-15 2016-09-21 Harvard College Procédés et compositions pour améliorer la détection et/ou la capture d'une entité cible
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3546474B1 (fr) 2013-12-18 2021-07-07 President and Fellows of Harvard College Capture/détection de bactéries gram positif à l'aide de crp
EP3266870A4 (fr) * 2015-03-05 2018-10-17 The University of Tokyo Conjugué et son utilisation
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
JP2020176065A (ja) * 2019-04-15 2020-10-29 共栄化学工業株式会社 皮膚外用剤
CA3137160A1 (fr) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
CN116463299A (zh) * 2023-04-04 2023-07-21 四川安可康生物医药有限公司 重组西尼罗河减毒病毒的疫苗、药物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US394906A (en) 1888-12-18 Calvin pi
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US20010031264A1 (en) * 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
BR9708387A (pt) * 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
WO1999061051A1 (fr) * 1998-05-26 1999-12-02 Genitrix, Lcc Compositions pour la modulation d'une reponse immunitaire face a un antigene et procede correspondant
WO2002041913A1 (fr) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectines utiles comme adjuvants

Also Published As

Publication number Publication date
WO2004018698A2 (fr) 2004-03-04
EP1573047B1 (fr) 2013-11-13
CA2496384C (fr) 2016-11-01
CA2496384A1 (fr) 2004-03-04
ES2441724T3 (es) 2014-02-06
MXPA05001953A (es) 2005-06-22
BR0313650A (pt) 2007-08-14
WO2004018698A3 (fr) 2007-08-23
JP2006517512A (ja) 2006-07-27
AU2003265523A1 (en) 2004-03-11
EP1573047A4 (fr) 2008-06-25
IL166998A (en) 2017-03-30
EP1573047A2 (fr) 2005-09-14
JP4892705B2 (ja) 2012-03-07

Similar Documents

Publication Publication Date Title
IL166998A (en) Preparation for the minor and methods for modulating the immune response to the antigen
ZA200501759B (en) Lectin compositions and methods for modulating an immune response to an antigen
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
EP1578930A4 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
IL164021A0 (en) Antibodies and anti-pharmaceutical compositions containing the same
AP2006003510A0 (en) Modified human IGF-1R antibodies.
AU2003301175A8 (en) Cross-domain transactions through simulated pop-ups
EP1551447A4 (fr) Anticorps anti-addl et leurs utilisations
EP1476456A4 (fr) Compositions et procede pour modulation de subroge-anticorps d'une reponse immunitaire et transport
EP1675617A4 (fr) Compositions et methodes visant a augmenter la fonction renale
AU2002309486A8 (en) Methods and compositions for modulating the immune system of animals
AU2003243058A8 (en) Methods for using the cd163 pathway for modulating an immune response
GB0220809D0 (en) Immune modulator
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
EP1492549A4 (fr) Compositions et procedes pour augmenter les fonctions renales
GB2422544B (en) Immune modulator
AU2003235799A8 (en) Modulation of iamt (pimt or pcmt) in immune system
IL175509A0 (en) Methods and agents for immune modulation
EP1539792A4 (fr) Polypeptides cngh0005, anticorps, compositions, methodes et utilisations
IL172510A0 (en) Antibodies and uses thereof
PL374439A1 (en) Antibodies and uses thereof
AU2003237332A8 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2003302234A8 (en) Immune response associated proteins
ZA200508729B (en) Anti-amyloid antibodies, compositions, methods and uses